Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
Total Valuation
Arcus Biosciences has a market cap or net worth of $859.79M. The enterprise value is $546.41M.
Market Cap$859.79M
Enterprise Value$546.41M
Share Statistics
Arcus Biosciences has 105,885,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105,885,140
Owned by Insiders6.46%
Owned by Institutions51.34%
Financial Efficiency
Arcus Biosciences’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -35.84%.
Return on Equity (ROE)-0.58
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-35.84%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee411.48K
Profits Per Employee-451.36K
Employee Count627
Asset Turnover0.22
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arcus Biosciences is -4.74. Arcus Biosciences’s PEG ratio is 0.19.
PE Ratio-4.74
PS Ratio0.00
PB Ratio2.77
Price to Fair Value2.77
Price to FCF-7.62
Price to Operating Cash Flow-7.89
PEG Ratio0.19
Income Statement
In the last 12 months, Arcus Biosciences had revenue of 258.00M and earned -283.00M in profits. Earnings per share was -3.14.
Revenue258.00M
Gross Profit258.00M
Operating Income-330.00M
Pretax Income-283.00M
Net Income-283.00M
EBITDA-269.00M
Earnings Per Share (EPS)-3.14
Cash Flow
In the last 12 months, operating cash flow was -170.00M and capital expenditures -6.00M, giving a free cash flow of -176.00M billion.
Operating Cash Flow-170.00M
Free Cash Flow-176.00M
Free Cash Flow per Share-1.66
Dividends & Yields
Arcus Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.02
52-Week Price Change-47.18%
50-Day Moving Average8.60
200-Day Moving Average13.73
Relative Strength Index (RSI)51.50
Average Volume (3m)1.17M
Important Dates
Arcus Biosciences upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Arcus Biosciences as a current ratio of 4.50, with Debt / Equity ratio of 12.37%
Current Ratio4.50
Quick Ratio4.50
Debt to Market Cap0.04
Net Debt to EBITDA0.38
Interest Coverage Ratio-82.50
Taxes
In the past 12 months, Arcus Biosciences has paid 1.00M in taxes.
Income Tax1.00M
Effective Tax Rate>-0.01
Enterprise Valuation
Arcus Biosciences EV to EBITDA ratio is -4.61, with an EV/FCF ratio of -7.04.
EV to Sales4.80
EV to EBITDA-4.61
EV to Free Cash Flow-7.04
EV to Operating Cash Flow-7.29
Balance Sheet
Arcus Biosciences has $978.00M in cash and marketable securities with ― in debt, giving a net cash position of -$918.00M billion.
Cash & Marketable Securities$978.00M
Total Debt―
Net Cash-$918.00M
Net Cash Per Share-$8.67
Tangible Book Value Per Share$5.38
Margins
Gross margin is 98.06%, with operating margin of -127.91%, and net profit margin of -109.69%.
Gross Margin98.06%
Operating Margin-127.91%
Pretax Margin-109.69%
Net Profit Margin-109.69%
EBITDA Margin-104.26%
EBIT Margin-108.14%
Analyst Forecast
The average price target for Arcus Biosciences is $29.11, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$29.11
Price Target Upside241.27% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast-40.51%
EPS Growth Forecast-35.07%